DISRUPT CAD III

By The Numbers

384
Patients
47
Global Sites
2
Year Follow-Up
30
Day MACE Rate = Primary Safety Endpoint
<50%
Residual Stenosis = Primary Effectiveness Endpoint
~100
Patient OCT Sub-Study

DISRUPT CAD III Study Leadership

dean j kereiakes md
Dean J. Kereiakes, M.D., FACC, FSCAI
Co-Principal Investigator
Medical Director, The Christ Hospital Heart and Vascular Center
Cincinnati, OH
jonathan hill
Jonathan Hill, M.D.
Co-Principal Investigator
Consultant Cardiologist King’s College Hospital
London, UK
gregg w stone
Gregg W. Stone, M.D., FACC, FSCAI
Study Chairman
Professor of Medicine, Columbia University Medical Center
New York City, NY

Countries Included in DISRUPT CAD III

World Map
United States
United States Info
United Kingdom
United Kingdom Info
France
France Info
Germany
Germany Info

Ready to Make Waves with Shockwave IVL?

ico email Connect
Disrupt

IT’S TIME TO

GET CRACKING

COUNTDOWN TO CAD III PRESENTATION

Days

Hours

Minutes

Seconds

TCT CONNECT

Caution: Investigational device. Limited by Federal (U.S.) law to investigational use.
ISI: https://shockwavemedical.com/important-safety-information-coronary/